Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

The Trump administration has moved to stop the supply of lifesaving drugs for HIV, malaria and tuberculosis, as well as ...

Study urges industry to be more transparent and fairer in selecting speakers, and to recruit more women to steering ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Pharmaceutical companies have already raised the price of over 800 brand-name prescription drugs this year. Nearly all the ...

Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

Citi lowered the firm’s price target on Merck (MRK) to $125 from $130 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the firm ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...